• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Bio-Techne Corporation Opens Production Center in St. Paul, Minnesota

Bio-Techne Corporation opened its approximately 61,000 square foot state-of-the-art GMP manufacturing facility in St. Paul, Minnesota.

The company invested roughly $50 million to build the new facility and equip it with the advanced manufacturing and quality control technologies needed to produce products for cell and gene therapies.

"Bio-Techne is the global leader in manufacturing research-grade proteins, with our R&D Systems brand widely recognized for the highest level of purity, bioreactivity and lot-to-lot consistency," Chuck Kummeth, Bio-Techne's President and CEO said.

"GMP proteins are an essential ingredient for the production of cell and gene therapies. With over 1,000 cell and gene therapies in various phases of clinical trials globally, we anticipate demand for GMP-grade proteins to dramatically increase going forward, representing a potential bottleneck in the cell and gene therapy workflow. Bio-Techne's global recognition combined with our state of the art GMP manufacturing facility positions us to meet global demand and further solidify our protein leadership position," he added.

According to company officials, the new facility is dedicated to supporting large-scale production of GMP-grade materials, including E. coli-derived recombinant proteins, which are an essential component for many immuno-oncology and regenerative medicine cell and gene-modified therapy workflows.

The process of culturing cells for therapeutic use requires precise amounts of specific biological proteins to support cell growth and development. Bio-Techne noted it has decades of experience in manufacturing these proteins. With multiple fermenters and purification suites, this new facility will now allow it to manufacture the large quantities of proteins under the GMP quality conditions required for use in the manufacturing of cells for therapeutic applications. Following extensive quality validation procedures, the facility is expected to begin production in early 2021.

Exclusive Research